===== phenotype 36=================================================================proportion of pts: 0.32904148784lambda: 798.418021768----------------------------------------Disorders of the peripheral nervous systemDisorders of the eye and adnexaArthropathies and related disordersDorsopathiesRheumatism, excluding the backSymptoms involving skin and other integumentary tissueAnalgesics, Non-NarcoticAnti-Allergic AgentsAnti-Bacterial AgentsAntihypertensive AgentsAntimanic AgentsAntineoplastic Agents, HormonalBone Density Conservation AgentsCyclooxygenase InhibitorsHistamine H1 Antagonists, Non-SedatingHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsNANitric Oxide DonorsPurinergic P2Y Receptor AntagonistsSodium Potassium Chloride Symporter InhibitorsSweetening AgentsVasodilator AgentsVitamin B Complex===== phenotype 45=================================================================proportion of pts: 0.22460658083lambda: 712.414755598----------------------------------------Disorders of the eye and adnexaDiseases of veins and lymphatics, and other diseases of circulatory systemDiseases of esophagus, stomach, and duodenumOther inflammatory conditions of skin and subcutaneous tissueOther diseases of skin and subcutaneous tissueSymptoms involving cardiovascular systemSymptoms involving urinary system14-alpha Demethylase InhibitorsAdrenergic alpha-1 Receptor AntagonistsAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAnti-Allergic AgentsAnti-Anxiety AgentsAnti-Asthmatic AgentsAnti-Inflammatory AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsAntimanic AgentsCardiotonic AgentsCyclooxygenase InhibitorsEnzyme InhibitorsEstrogensFree Radical ScavengersGABA-A Receptor AgonistsGlucocorticoidsHistamine H1 Antagonists, Non-SedatingHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsImmunosuppressive AgentsMineralocorticoid Receptor AntagonistsNANarcoticsProton Pump InhibitorsSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsTopoisomerase II Inhibitors===== phenotype 34=================================================================proportion of pts: 0.290414878398lambda: 667.624130214----------------------------------------DiabetesDisorders of lipoid metabolismHypertensive diseaseNonspecific findings on examination of bloodRange name naAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAnti-Inflammatory AgentsAntihypertensive AgentsBone Density Conservation AgentsCyclooxygenase InhibitorsGlucocorticoidsHydroxymethylglutaryl-CoA Reductase InhibitorsNAProton Pump InhibitorsRodenticidesSurface-Active AgentsVitamin B ComplexVitamins===== phenotype 26=================================================================proportion of pts: 0.247496423462lambda: 653.322573129----------------------------------------Diseases of veins and lymphatics, and other diseases of circulatory systemAcute respiratory infectionsOther diseases of the upper respiratory tractInfections of skin and subcutaneous tissueOther diseases of skin and subcutaneous tissueSymptoms involving head and neck14-alpha Demethylase InhibitorsAdrenergic alpha-1 Receptor AntagonistsAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAntacidsAnti-Allergic AgentsAnti-Bacterial AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsAntimalarialsAntimanic AgentsBone Density Conservation AgentsCyclooxygenase InhibitorsHistamine H1 Antagonists, Non-SedatingHydroxymethylglutaryl-CoA Reductase InhibitorsMineralocorticoid Receptor AntagonistsMuscarinic AntagonistsNARodenticidesSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsVasodilator AgentsVitamins===== phenotype 5=================================================================proportion of pts: 0.218884120172lambda: 628.178684221----------------------------------------AnemiasOrganic sleep disordersDiseases of oral cavity, salivary glands, and jawsArthropathies and related disordersSymptoms involving head and neckSprains and strains of joints and adjacent musclesAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAnti-Allergic AgentsAnti-Bacterial AgentsAnti-Inflammatory AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsAntimanic AgentsAntiviral AgentsBone Density Conservation AgentsCardiotonic AgentsCyclooxygenase InhibitorsDopamine Uptake InhibitorsGABA ModulatorsGABA-A Receptor AgonistsGastrointestinal AgentsHistamine H1 AntagonistsHistamine H1 Antagonists, Non-SedatingHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsMineralocorticoid Receptor AntagonistsNANarcoticsNitric Oxide DonorsProton Pump InhibitorsSodium Potassium Chloride Symporter InhibitorsSweetening AgentsVasodilator AgentsVitamin B Complex===== phenotype 15=================================================================proportion of pts: 0.203147353362lambda: 602.848928243----------------------------------------Disorders of thyroid glandDisorders of lipoid metabolismDisorders of the eye and adnexaHypertensive diseaseGeneral symptomsSymptoms involving respiratory system and other chest symptomsRange name na14-alpha Demethylase InhibitorsAdrenergic alpha-2 Receptor AgonistsAntacidsAnti-Bacterial AgentsAntihypertensive AgentsAntimutagenic AgentsBone Density Conservation AgentsCardiotonic AgentsCyclooxygenase 2 InhibitorsEpithelial Sodium Channel BlockersGABA ModulatorsHistamine H1 AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsNANeuroprotective AgentsNicotinic AgonistsSodium Chloride Symporter InhibitorsVitamin B ComplexVitamins===== phenotype 20=================================================================proportion of pts: 0.247496423462lambda: 594.170835442----------------------------------------Disorders of lipoid metabolismDiseases of the ear and mastoid processHypertensive diseaseOther diseases of the upper respiratory tractOther diseases of skin and subcutaneous tissueSymptoms involving respiratory system and other chest symptomsAdrenergic beta-1 Receptor AntagonistsAnti-Allergic AgentsAnti-Bacterial AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsAntimanic AgentsAntiviral AgentsBone Density Conservation AgentsCardiotonic AgentsCyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsEstrogensGABA ModulatorsHistamine H1 Antagonists, Non-SedatingHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsImmunosuppressive AgentsMuscle Relaxants, CentralNANarcoticsParasympatholyticsProton Pump InhibitorsTopoisomerase II InhibitorsVasodilator Agents===== phenotype 13=================================================================proportion of pts: 0.195994277539lambda: 561.36963012----------------------------------------Neurotic, personality, nonpsychotic disordersDiseases of arteries, arterioles, and capillariesArthropathies and related disordersRheumatism, excluding the backAbnormal results of function studiesRange name naAdrenergic alpha-1 Receptor AntagonistsAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-2 Receptor AgonistsAnalgesics, Non-NarcoticAnti-Asthmatic AgentsAnticholesteremic AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsCardiotonic AgentsCyclooxygenase InhibitorsEstrogensExplosive AgentsGABA ModulatorsGABA-A Receptor AgonistsHistamine H1 AntagonistsHistamine H2 AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsMuscle Relaxants, CentralNAParasympatholyticsProton Pump InhibitorsSodium Chloride Symporter InhibitorsSurface-Active AgentsVasodilator Agents===== phenotype 38=================================================================proportion of pts: 0.241773962804lambda: 554.53885211----------------------------------------Other diseases of urinary systemOther inflammatory conditions of skin and subcutaneous tissueDorsopathiesSymptoms involving cardiovascular systemSymptoms involving urinary systemAdrenergic alpha-1 Receptor AntagonistsAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-2 Receptor AgonistsAnesthetics, IntravenousAnti-Bacterial AgentsAntihypertensive AgentsAntimanic AgentsCardiotonic AgentsCyclooxygenase InhibitorsDopamine Uptake InhibitorsGABA ModulatorsHydroxymethylglutaryl-CoA Reductase InhibitorsMuscle Relaxants, CentralNANarcoticsParasympatholyticsSurface-Active AgentsSympathomimeticsTopoisomerase II InhibitorsVasodilator AgentsVitamins===== phenotype 37=================================================================proportion of pts: 0.234620886981lambda: 548.437988976----------------------------------------Hypertensive diseaseIschemic heart diseaseOther diseases of urinary systemGeneral symptomsSymptoms involving urinary systemRange name naAdrenergic alpha-1 Receptor AntagonistsAnalgesics, Non-NarcoticAnti-Allergic AgentsAntiviral AgentsBone Density Conservation AgentsDopamine AntagonistsEstrogensHistamine H1 AntagonistsHistamine H1 Antagonists, Non-SedatingHypoglycemic AgentsImmunosuppressive AgentsNASodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsTopoisomerase II InhibitorsVitamin B ComplexVitamins===== phenotype 4=================================================================proportion of pts: 0.178826895565lambda: 543.130797274----------------------------------------Disorders of lipoid metabolismAnemiasHypertensive diseaseArthropathies and related disordersRheumatism, excluding the backOsteopathies, chondropathies, and acquired musculoskeletal deformitiesRange name na14-alpha Demethylase InhibitorsAdrenergic alpha-1 Receptor AntagonistsAngiotensin II Type 1 Receptor BlockersAnti-Asthmatic AgentsAnti-Inflammatory AgentsAntihypertensive AgentsAntimanic AgentsCholinergic AntagonistsFree Radical ScavengersGABA-A Receptor AgonistsGlucocorticoidsHypoglycemic AgentsImmunosuppressive AgentsNANarcoticsNucleic Acid Synthesis InhibitorsSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsTopoisomerase II InhibitorsTrace ElementsVoltage-Gated Sodium Channel Blockers===== phenotype 10=================================================================proportion of pts: 0.231759656652lambda: 542.409573015----------------------------------------NaDisorders of the eye and adnexaChronic obstructive pulmonary disease and allied conditionsOther diseases of intestines and peritoneumInfections of skin and subcutaneous tissueAbnormal results of function studiesAdrenergic alpha-1 Receptor AntagonistsAnalgesics, Non-NarcoticAnti-Allergic AgentsAnti-Anxiety AgentsAnti-Bacterial AgentsAnti-Inflammatory AgentsAntineoplastic Agents, HormonalAntiviral AgentsCardiotonic AgentsCholinergic AntagonistsCyclooxygenase InhibitorsDopamine Uptake InhibitorsGABA-A Receptor AgonistsHistamine H1 Antagonists, Non-SedatingHypoglycemic AgentsImmunosuppressive AgentsNANarcoticsProton Pump InhibitorsSodium Chloride Symporter InhibitorsSurface-Active AgentsSympathomimeticsVasodilator AgentsVitamin B ComplexVoltage-Gated Sodium Channel Blockers===== phenotype 33=================================================================proportion of pts: 0.211731044349lambda: 530.882656349----------------------------------------Nutritional deficienciesDisorders of lipoid metabolismDisorders of the eye and adnexaDiseases of the ear and mastoid processHypertensive diseaseArthropathies and related disordersAdrenergic alpha-1 Receptor AntagonistsAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAndrogensAngiotensin II Type 1 Receptor BlockersAnti-Bacterial AgentsAnti-Inflammatory Agents, Non-SteroidalAntimanic AgentsCyclooxygenase InhibitorsGABA ModulatorsGastrointestinal AgentsHypoglycemic AgentsNANarcoticsNootropic AgentsPhosphodiesterase 5 InhibitorsProton Pump InhibitorsSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsSurface-Active AgentsVasodilator AgentsVitamin B Complex===== phenotype 46=================================================================proportion of pts: 0.200286123033lambda: 522.601866659----------------------------------------DiabetesDisorders of lipoid metabolismHypertensive diseaseIschemic heart diseaseSymptoms involving respiratory system and other chest symptomsRange name naAdrenergic alpha-1 Receptor AntagonistsAngiotensin II Type 1 Receptor BlockersAnti-Bacterial AgentsAntimanic AgentsAntioxidantsBone Density Conservation AgentsChelating AgentsCyclooxygenase InhibitorsExplosive AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsMineralocorticoid Receptor AntagonistsNANitric Oxide DonorsNootropic AgentsSodium Potassium Chloride Symporter InhibitorsSweetening AgentsVasodilator AgentsVitamins===== phenotype 1=================================================================proportion of pts: 0.230329041488lambda: 509.828991393----------------------------------------Disorders of lipoid metabolismHypertensive diseaseIschemic heart diseaseOther forms of heart diseaseAcute respiratory infectionsArthropathies and related disordersAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-2 Receptor AgonistsAnti-Allergic AgentsAnti-Asthmatic AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsCardiotonic AgentsCholinergic AntagonistsExplosive AgentsGABA ModulatorsHydroxymethylglutaryl-CoA Reductase InhibitorsProton Pump InhibitorsSodium Chloride Symporter InhibitorsSympatholyticsTranquilizing AgentsVitamins===== phenotype 44=================================================================proportion of pts: 0.233190271817lambda: 505.643382186----------------------------------------Benign neoplasm of other parts of digestive systemDisorders of the eye and adnexaOther diseases of intestines and peritoneumRheumatism, excluding the backGeneral symptomsSymptoms involving respiratory system and other chest symptomsAdrenergic alpha-1 Receptor AntagonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsCyclooxygenase InhibitorsExplosive AgentsGABA ModulatorsGlucocorticoidsHistamine H1 Antagonists, Non-SedatingHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsHypolipidemic AgentsImmunosuppressive AgentsNAProton Pump InhibitorsSympathomimeticsVasodilator AgentsVitamins===== phenotype 42=================================================================proportion of pts: 0.217453505007lambda: 496.957809084----------------------------------------Neurotic, personality, nonpsychotic disordersIschemic heart diseaseOther disorders of female genital tractGeneral symptomsSymptoms involving digestive systemOther symptoms involving abdomen and pelvisAdrenergic Uptake InhibitorsAdrenergic alpha-2 Receptor AgonistsAnalgesics, Non-NarcoticAnti-Allergic AgentsAnti-Bacterial AgentsAnti-Inflammatory AgentsAntihypertensive AgentsAntimanic AgentsAntiviral AgentsCardiotonic AgentsCyclooxygenase InhibitorsEnzyme InhibitorsEstrogensExpectorantsExplosive AgentsGABA ModulatorsGlucocorticoidsHistamine H1 Antagonists, Non-SedatingHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsNANucleic Acid Synthesis InhibitorsParasympatholyticsSerotonin Uptake Inhibitors===== phenotype 43=================================================================proportion of pts: 0.14878397711lambda: 494.078025976----------------------------------------Overweight, obesity and other hyperalimentationOther diseases of the bloodDrug dependenceChronic obstructive pulmonary disease and allied conditionsSymptoms involving respiratory system and other chest symptomsIll-defined and unknown causes of morbidity and mortalityMiscellaneous diagnostic and therapeutic procedures14-alpha Demethylase InhibitorsAdrenergic Uptake InhibitorsAdrenergic alpha-1 Receptor AntagonistsAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAnti-Allergic AgentsAnti-Bacterial AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsAntimanic AgentsBone Density Conservation AgentsCardiotonic AgentsCyclooxygenase InhibitorsDopamine Uptake InhibitorsFluorescent DyesGlucocorticoidsHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsMineralocorticoid Receptor AntagonistsNANootropic AgentsProton Pump InhibitorsSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsTopoisomerase II InhibitorsTubulin ModulatorsVasodilator Agents===== phenotype 24=================================================================proportion of pts: 0.211731044349lambda: 493.535553651----------------------------------------Acute respiratory infectionsPneumonia and influenzaCongenital anomaliesSymptoms involving digestive systemAbnormal results of function studiesFracturesAdrenergic alpha-1 Receptor AntagonistsAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-2 Receptor AgonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAntacidsAnti-Bacterial AgentsAntimanic AgentsBone Density Conservation AgentsCardiotonic AgentsCyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsGABA ModulatorsHistamine H1 Antagonists, Non-SedatingHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsImmunosuppressive AgentsNAProton Pump InhibitorsSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsTopoisomerase II InhibitorsVasodilator AgentsVitamin B ComplexVitamins===== phenotype 29=================================================================proportion of pts: 0.178826895565lambda: 474.39163438----------------------------------------Neoplasm of uncertain behavior of other sites & tissuesHypertensive diseaseOther forms of heart diseaseOther diseases of skin and subcutaneous tissueArthropathies and related disordersSymptoms involving skin and other integumentary tissueAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-1 Receptor AntagonistsAnti-Allergic AgentsAntimanic AgentsAntineoplastic Agents, HormonalAntiviral AgentsBone Density Conservation AgentsCardiotonic AgentsCyclooxygenase InhibitorsEnzyme InhibitorsEpithelial Sodium Channel BlockersGABA-A Receptor AgonistsHypoglycemic AgentsNAProton Pump InhibitorsSodium Chloride Symporter InhibitorsSurface-Active AgentsVasodilator AgentsVitamin B ComplexVitamins===== phenotype 12=================================================================proportion of pts: 0.165951359084lambda: 467.960820106----------------------------------------Symptoms involving skin and other integumentary tissueSymptoms involving cardiovascular systemFracturesCertain traumatic complications and unspecified injuriesComplications of surgical and medical care, not elsewhere classifiedRange name naAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAnti-Allergic AgentsAnti-Bacterial AgentsAnti-Inflammatory AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsAntimalarialsCatharticsChelating AgentsCyclooxygenase InhibitorsDopamine AntagonistsDopamine Uptake InhibitorsEnzyme InhibitorsFree Radical ScavengersGABA ModulatorsHydroxymethylglutaryl-CoA Reductase InhibitorsImmunosuppressive AgentsNANucleic Acid Synthesis InhibitorsProton Pump InhibitorsSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsTopoisomerase II InhibitorsTrace ElementsVasodilator AgentsVoltage-Gated Sodium Channel Blockers===== phenotype 28=================================================================proportion of pts: 0.153075822604lambda: 456.559506186----------------------------------------MycosesDisorders of the peripheral nervous systemOther diseases of the upper respiratory tractOther diseases of urinary systemSymptoms involving skin and other integumentary tissueNonspecific findings on examination of blood14-alpha Demethylase InhibitorsAdrenergic Uptake InhibitorsAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-2 Receptor AgonistsAnalgesics, Non-NarcoticAnti-Allergic AgentsAnti-Asthmatic AgentsAnti-Bacterial AgentsAntimanic AgentsAntineoplastic Agents, HormonalAntitussive AgentsBone Density Conservation AgentsCardiotonic AgentsCyclooxygenase InhibitorsEnzyme InhibitorsGABA ModulatorsGastrointestinal AgentsHistamine H2 AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsMineralocorticoid Receptor AntagonistsMuscle Relaxants, CentralNANucleic Acid Synthesis InhibitorsProton Pump InhibitorsSerotonin 5-HT1 Receptor AgonistsSerotonin Uptake InhibitorsSodium Potassium Chloride Symporter InhibitorsSympathomimeticsTopoisomerase II InhibitorsVasodilator AgentsVoltage-Gated Sodium Channel Blockers===== phenotype 31=================================================================proportion of pts: 0.174535050072lambda: 451.652998792----------------------------------------AnemiasCoagulation or hemorrhagic diseasesDrug dependenceCerebrovascular diseaseSymptoms involving nervous and musculoskeletal systemsMiscellaneous diagnostic and therapeutic proceduresAdrenergic alpha-1 Receptor AntagonistsAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAnti-Bacterial AgentsAntihypertensive AgentsAntimanic AgentsAntineoplastic Agents, HormonalCardiotonic AgentsCatharticsCyclooxygenase InhibitorsFree Radical ScavengersHistamine H1 AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsNANarcoticsProton Pump InhibitorsPurinergic P2Y Receptor AntagonistsRodenticidesSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsSurface-Active AgentsSweetening AgentsSympathomimeticsVasodilator AgentsVitamin B ComplexVitaminsVoltage-Gated Sodium Channel Blockers===== phenotype 35=================================================================proportion of pts: 0.171673819742lambda: 435.236534596----------------------------------------Nutritional deficienciesDiseases of the ear and mastoid processOther diseases of intestines and peritoneumOsteopathies, chondropathies, and acquired musculoskeletal deformitiesGeneral symptomsAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAnti-Allergic AgentsAnti-Asthmatic AgentsAnti-Bacterial AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsBone Density Conservation AgentsCyclooxygenase InhibitorsExplosive AgentsGlucocorticoidsHistamine H1 Antagonists, Non-SedatingMineralocorticoid Receptor AntagonistsNANarcoticsProton Pump InhibitorsSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsTopoisomerase II InhibitorsVitamin B ComplexVitamins===== phenotype 7=================================================================proportion of pts: 0.218884120172lambda: 434.432836433----------------------------------------Other bacterial diseasesMalignant neoplasm of skinDiseases of other endocrine glandsAnemiasHereditary and degenerative diseases of the central nervous systemDiseases of male genital organsAdrenergic alpha-1 Receptor AntagonistsAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAnti-Allergic AgentsAnti-Bacterial AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsAntimanic AgentsCardiotonic AgentsCyclooxygenase InhibitorsGABA ModulatorsHistamine H1 Antagonists, Non-SedatingHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsMineralocorticoid Receptor AntagonistsNAProton Pump InhibitorsRodenticidesSodium Potassium Chloride Symporter InhibitorsVasodilator AgentsVitamin B Complex===== phenotype 19=================================================================proportion of pts: 0.168812589413lambda: 414.326604824----------------------------------------Overweight, obesity and other hyperalimentationPainOther disorders of the central nervous systemChronic obstructive pulmonary disease and allied conditionsHernia of abdominal cavitySymptoms involving skin and other integumentary tissueNonspecific abnormal findings on radiological and other examination of body structureAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-2 Receptor AgonistsAnalgesics, Non-NarcoticAnti-Allergic AgentsAnti-Asthmatic AgentsAnti-Bacterial AgentsAntidepressive Agents, Second-GenerationAntimanic AgentsAntioxidantsCalcium Channel BlockersCardiotonic AgentsCyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsExplosive AgentsGABA ModulatorsHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsImmunosuppressive AgentsNANarcoticsNicotinic AgonistsParasympatholyticsProton Pump InhibitorsPurinergic P2Y Receptor AntagonistsSerotonin 5-HT1 Receptor AgonistsSodium Potassium Chloride Symporter InhibitorsSurface-Active AgentsVasodilator AgentsVitamins===== phenotype 2=================================================================proportion of pts: 0.155937052933lambda: 411.689126705----------------------------------------Other diseases of the bloodIschemic heart diseaseOther forms of heart diseaseGeneral symptomsMiscellaneous diagnostic and therapeutic proceduresAdrenergic alpha-1 Receptor AntagonistsAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAnti-Asthmatic AgentsAntihypertensive AgentsAntimalarialsAntimanic AgentsAntineoplastic Agents, HormonalCyclooxygenase InhibitorsEnzyme InhibitorsEpithelial Sodium Channel BlockersExplosive AgentsFree Radical ScavengersGABA ModulatorsGastrointestinal AgentsHistamine H1 Antagonists, Non-SedatingNANarcoticsNitric Oxide DonorsProton Pump InhibitorsRodenticidesSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsSurface-Active AgentsTopoisomerase II InhibitorsVasodilator Agents===== phenotype 3=================================================================proportion of pts: 0.18025751073lambda: 411.37035428----------------------------------------Nutritional deficienciesDorsopathiesRheumatism, excluding the backSymptoms involving respiratory system and other chest symptomsAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-2 Receptor AgonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAnti-Allergic AgentsAnti-Asthmatic AgentsBone Density Conservation AgentsCardiotonic AgentsCyclooxygenase InhibitorsGABA-A Receptor AgonistsHistamine H2 AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsNAProton Pump InhibitorsSympathomimeticsVasodilator AgentsVitamin B ComplexVitamins===== phenotype 16=================================================================proportion of pts: 0.125894134478lambda: 386.378377766----------------------------------------Hypertensive diseaseOther forms of heart diseaseNephritis, nephrotic syndrome, and nephrosisArthropathies and related disordersSymptoms involving respiratory system and other chest symptomsAdrenergic Uptake InhibitorsAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAnti-Allergic AgentsAnti-Bacterial AgentsAntihypertensive AgentsAntimalarialsAntimanic AgentsAntineoplastic Agents, AlkylatingCyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsEnzyme InhibitorsExplosive AgentsGABA ModulatorsHypoglycemic AgentsMuscarinic AntagonistsNAProton Pump InhibitorsPurinergic P2Y Receptor AntagonistsRodenticidesSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsSympathomimeticsVasodilator AgentsVoltage-Gated Sodium Channel Blockers===== phenotype 0=================================================================proportion of pts: 0.171673819742lambda: 383.577317643----------------------------------------Hypertensive diseaseAcute respiratory infectionsOther diseases of intestines and peritoneumArthropathies and related disordersGeneral symptomsRange name naAdrenergic alpha-1 Receptor AntagonistsAnalgesics, Non-NarcoticAnesthetics, IntravenousAngiotensin II Type 1 Receptor BlockersAntacidsAnti-Anxiety AgentsAntimanic AgentsGABA ModulatorsGABA-A Receptor AgonistsHypoglycemic AgentsMineralocorticoid Receptor AntagonistsNANeuroprotective AgentsProton Pump InhibitorsSerotonin Uptake InhibitorsSympathomimeticsTopoisomerase II InhibitorsVasodilator AgentsVitamin B Complex===== phenotype 18=================================================================proportion of pts: 0.135908440629lambda: 381.124360381----------------------------------------Hypertensive diseaseDiseases of male genital organsOther inflammatory conditions of skin and subcutaneous tissueDorsopathiesSymptoms involving respiratory system and other chest symptomsRange name naAdrenergic alpha-1 Receptor AntagonistsAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAntacidsAnti-Allergic AgentsAnti-Asthmatic AgentsAnti-Bacterial AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsAntioxidantsAntiviral AgentsCyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDopamine Uptake InhibitorsEnzyme InhibitorsFree Radical ScavengersGABA-A Receptor AgonistsHistamine H1 Antagonists, Non-SedatingHistamine H2 AntagonistsMineralocorticoid Receptor AntagonistsNAParasympatholyticsProton Pump InhibitorsPurinergic P1 Receptor AntagonistsSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsTrace ElementsVasodilator AgentsViscosupplementsVitamins===== phenotype 40=================================================================proportion of pts: 0.113018597997lambda: 376.110559002----------------------------------------Other bacterial diseasesNeurotic, personality, nonpsychotic disordersOther diseases of respiratory systemOther diseases of intestines and peritoneumOperations on the musculoskeletal systemOther and unspecified effects of external causes14-alpha Demethylase InhibitorsAdrenergic Uptake InhibitorsAdrenergic alpha-1 Receptor AntagonistsAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-AntagonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAnti-Bacterial AgentsAnti-Infective Agents, LocalAnti-Inflammatory AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsBone Density Conservation AgentsCardiotonic AgentsCariostatic AgentsCatharticsChelating AgentsCyclooxygenase InhibitorsEnzyme InhibitorsFree Radical ScavengersGABA ModulatorsGlucocorticoidsHematinicsHistamine H2 AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsNANucleic Acid Synthesis InhibitorsProton Pump InhibitorsSerotonin Uptake InhibitorsSodium Potassium Chloride Symporter InhibitorsSurface-Active AgentsSympathomimeticsVasodilator AgentsVitamins===== phenotype 41=================================================================proportion of pts: 0.171673819742lambda: 366.756404651----------------------------------------Disorders of breastOther disorders of female genital tractSymptoms concerning nutrition, metabolism, and developmentCertain traumatic complications and unspecified injuriesAdrenergic alpha-1 Receptor AntagonistsAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAnti-Allergic AgentsAntidepressive Agents, Second-GenerationAntimanic AgentsAntimutagenic AgentsBone Density Conservation AgentsCardiotonic AgentsCyclooxygenase InhibitorsGABA ModulatorsGABA-A Receptor AgonistsHistamine H1 Antagonists, Non-SedatingHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsHypolipidemic AgentsImmunosuppressive AgentsNANarcoticsProton Pump InhibitorsRodenticidesSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsSurface-Active AgentsSweetening AgentsVasodilator AgentsVitamin B ComplexVitaminsVoltage-Gated Sodium Channel Blockers===== phenotype 48=================================================================proportion of pts: 0.140200286123lambda: 352.272210265----------------------------------------NaLiverArthropathies and related disordersGeneral symptomsAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-2 Receptor AgonistsAnalgesics, Non-NarcoticAndrogensAngiotensin II Type 1 Receptor BlockersAnti-Bacterial AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsAntimanic AgentsBone Density Conservation AgentsCalcium Channel BlockersCardiotonic AgentsCyclooxygenase InhibitorsDopamine Uptake InhibitorsEstrogensFood AdditivesFree Radical ScavengersGABA ModulatorsGastrointestinal AgentsHistamine H1 Antagonists, Non-SedatingHistamine H2 AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsMineralocorticoid Receptor AntagonistsNANarcoticsParasympatholyticsProton Pump InhibitorsSodium Chloride Symporter InhibitorsTopoisomerase II InhibitorsVasodilator Agents===== phenotype 17=================================================================proportion of pts: 0.157367668097lambda: 343.404469355----------------------------------------Disorders of lipoid metabolismOther diseases of urinary systemDorsopathiesSymptoms involving digestive systemAdrenergic Uptake InhibitorsAdrenergic alpha-1 Receptor AntagonistsAnalgesics, Non-NarcoticAnti-Allergic AgentsAnti-Obesity AgentsAntidepressive Agents, Second-GenerationAntimanic AgentsAntineoplastic Agents, HormonalCalcium Channel BlockersCardiotonic AgentsCatharticsDopamine AntagonistsEstrogensGastrointestinal AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsMineralocorticoid Receptor AntagonistsMuscarinic AntagonistsNANarcoticsParasympatholyticsProton Pump InhibitorsRodenticidesSodium Potassium Chloride Symporter InhibitorsSweetening AgentsSympathomimeticsTranquilizing AgentsVasodilator Agents===== phenotype 22=================================================================proportion of pts: 0.134477825465lambda: 339.092214012----------------------------------------Drug dependenceOther disorders of the central nervous systemOther diseases of the upper respiratory tractOther diseases of respiratory systemDiseases of male genital organsArthropathies and related disordersSymptoms involving head and neckAdrenergic alpha-1 Receptor AntagonistsAdrenergic beta-2 Receptor AgonistsAnesthetics, IntravenousAngiotensin II Type 1 Receptor BlockersAnti-Allergic AgentsAnti-Anxiety AgentsAnti-Asthmatic AgentsAnti-Bacterial AgentsAnti-Inflammatory AgentsAntineoplastic Agents, HormonalCyclooxygenase InhibitorsExplosive AgentsFibrinolytic AgentsHistamine H1 Antagonists, Non-SedatingHypoglycemic AgentsImmunosuppressive AgentsIndicators and ReagentsNANitric Oxide DonorsProton Pump InhibitorsPurinergic P2Y Receptor AntagonistsSodium Chloride Symporter InhibitorsSurface-Active AgentsVasodilator AgentsVoltage-Gated Sodium Channel Blockers===== phenotype 6=================================================================proportion of pts: 0.1330472103lambda: 338.728805705----------------------------------------Disorders of lipoid metabolismDiseases of esophagus, stomach, and duodenumOther diseases of intestines and peritoneumOther diseases of urinary systemOther symptoms involving abdomen and pelvisAdrenergic alpha-2 Receptor AgonistsAnalgesics, Non-NarcoticAnesthetics, IntravenousAnti-Allergic AgentsAntidepressive Agents, Second-GenerationAntimalarialsBone Density Conservation AgentsCardiotonic AgentsCyclooxygenase 2 InhibitorsEpithelial Sodium Channel BlockersEstrogensHistamine H1 AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsImmunosuppressive AgentsNANarcoticsPhosphodiesterase 5 InhibitorsProton Pump InhibitorsSurface-Active AgentsVitamins===== phenotype 47=================================================================proportion of pts: 0.177396280401lambda: 336.887733109----------------------------------------Other diseases of respiratory systemSymptoms involving cardiovascular systemSymptoms involving respiratory system and other chest symptomsOther and unspecified effects of external causesAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-AntagonistsAnalgesics, Non-NarcoticAnesthetics, IntravenousAnti-Allergic AgentsAnti-Bacterial AgentsAntihypertensive AgentsAntiviral AgentsBone Density Conservation AgentsEnzyme InhibitorsExplosive AgentsGABA-A Receptor AgonistsHydroxymethylglutaryl-CoA Reductase InhibitorsMuscarinic AntagonistsNANarcoticsNitric Oxide DonorsPhosphodiesterase 5 InhibitorsPurinergic P2Y Receptor AntagonistsRodenticidesSodium Chloride Symporter InhibitorsSurface-Active AgentsSweetening AgentsVasodilator AgentsVitamins===== phenotype 32=================================================================proportion of pts: 0.12017167382lambda: 335.716194075----------------------------------------Organic sleep disordersHereditary and degenerative diseases of the central nervous systemDiseases of esophagus, stomach, and duodenumOther diseases of digestive systemOther symptoms involving abdomen and pelvisAdrenergic alpha-1 Receptor AntagonistsAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-2 Receptor AgonistsAnesthetics, IntravenousAnti-Allergic AgentsAnti-Bacterial AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsAntimanic AgentsAntimutagenic AgentsAntioxidantsBone Density Conservation AgentsCalcium Channel BlockersCardiotonic AgentsCatharticsChelating AgentsDopamine AntagonistsDopamine Uptake InhibitorsGABA ModulatorsGastrointestinal AgentsHypoglycemic AgentsHypolipidemic AgentsIndicators and ReagentsMineralocorticoid Receptor AntagonistsNANeuroprotective AgentsPhosphodiesterase 5 InhibitorsSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsSympathomimeticsVasodilator AgentsVitamins===== phenotype 8=================================================================proportion of pts: 0.124463519313lambda: 305.772615562----------------------------------------Secondary malignant neoplasm of lymph nodes, digestive system and other specified sitesDisorders of thyroid glandAcute respiratory infectionsOther diseases of the upper respiratory tractRheumatism, excluding the backAdrenergic alpha-1 Receptor AntagonistsAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAnti-Allergic AgentsAnti-Bacterial AgentsAnti-Inflammatory AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsAntimanic AgentsCardiotonic AgentsCholinergic AntagonistsCyclooxygenase InhibitorsEstrogensFree Radical ScavengersGABA-A Receptor AgonistsHistamine H2 AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsHypolipidemic AgentsNANarcoticsNucleic Acid Synthesis InhibitorsProton Pump InhibitorsSodium Potassium Chloride Symporter InhibitorsSweetening AgentsTopoisomerase II InhibitorsVasodilator AgentsVoltage-Gated Sodium Channel Blockers===== phenotype 30=================================================================proportion of pts: 0.0944206008584lambda: 303.494741882----------------------------------------MycosesDisorders of the peripheral nervous systemOther diseases of intestines and peritoneumOther diseases of skin and subcutaneous tissueDorsopathiesSymptoms involving skin and other integumentary tissueAdrenergic beta-AntagonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAnti-Allergic AgentsAnti-Bacterial AgentsAnti-Inflammatory AgentsAntidepressive Agents, Second-GenerationAntimanic AgentsAntineoplastic Agents, AlkylatingBone Density Conservation AgentsCholinergic AntagonistsCyclooxygenase InhibitorsDopamine Uptake InhibitorsEstrogensGlucocorticoidsHistamine H1 AntagonistsKeratolytic AgentsNANucleic Acid Synthesis InhibitorsProton Pump InhibitorsSweetening AgentsSympathomimeticsVoltage-Gated Sodium Channel Blockers===== phenotype 39=================================================================proportion of pts: 0.12017167382lambda: 301.418935763----------------------------------------Chronic rheumatic heart diseaseDiseases of pulmonary circulationOther diseases of respiratory systemNonspecific findings on examination of bloodNonspecific findings on examination of urineAdrenergic alpha-1 Receptor AntagonistsAdrenergic beta-1 Receptor AntagonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAntacidsAnti-Allergic AgentsAnti-Bacterial AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsAntimanic AgentsAntiviral AgentsBone Density Conservation AgentsCardiotonic AgentsCyclooxygenase InhibitorsGABA ModulatorsHistamine H1 Antagonists, Non-SedatingHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsMineralocorticoid Receptor AntagonistsNASodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsVasodilator AgentsVitamin B ComplexVitamins===== phenotype 9=================================================================proportion of pts: 0.138769670959lambda: 299.211275013----------------------------------------MycosesDiabetesRheumatism, excluding the backRange name naAdrenergic alpha-1 Receptor AntagonistsAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-AntagonistsAnalgesics, Non-NarcoticAntihypertensive AgentsAntimanic AgentsAntineoplastic Agents, AlkylatingCardiotonic AgentsCatharticsCholinergic AntagonistsDopamine AntagonistsEnzyme InhibitorsEstrogensGABA ModulatorsGastrointestinal AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsMyeloablative AgonistsNANootropic AgentsSodium Chloride Symporter InhibitorsSweetening AgentsVasodilator AgentsVitamin B Complex===== phenotype 21=================================================================proportion of pts: 0.1330472103lambda: 294.914976655----------------------------------------Hernia of abdominal cavitySymptoms involving nervous and musculoskeletal systemsOpen woundComplications of surgical and medical care, not elsewhere classifiedAdrenergic alpha-1 Receptor AntagonistsAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-2 Receptor AgonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAntacidsAnti-Allergic AgentsAnti-Bacterial AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsAntimanic AgentsBone Density Conservation AgentsCardiotonic AgentsCholinergic AntagonistsCyclooxygenase InhibitorsEstrogensGABA ModulatorsGABA-A Receptor AgonistsHistamine H2 AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsNANarcoticsProton Pump InhibitorsSodium Potassium Chloride Symporter InhibitorsSurface-Active AgentsVasodilator Agents===== phenotype 11=================================================================proportion of pts: 0.123032904149lambda: 266.780677218----------------------------------------PainDisorders of the peripheral nervous systemArthropathies and related disordersOther nonspecific abnormal findings5-alpha Reductase InhibitorsAdrenergic alpha-1 Receptor AntagonistsAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-2 Receptor AgonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAnti-Allergic AgentsAnti-Bacterial AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsAntimanic AgentsAntioxidantsAntiviral AgentsBone Density Conservation AgentsCardiotonic AgentsCyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsEstrogensFree Radical ScavengersGABA ModulatorsGABA-A Receptor AgonistsHydroxymethylglutaryl-CoA Reductase InhibitorsImmunosuppressive AgentsNAParasympatholyticsProton Pump InhibitorsSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsTrace ElementsVasodilator AgentsVitamin B ComplexVitamins===== phenotype 27=================================================================proportion of pts: 0.128755364807lambda: 263.760790567----------------------------------------Disorders of fluid, electrolyte, and acid-base balanceAnemiasOther diseases of urinary systemSymptoms involving urinary systemAdrenergic alpha-1 Receptor AntagonistsAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-2 Receptor AgonistsAnalgesics, Non-NarcoticAndrogensAnti-Allergic AgentsAntidepressive Agents, Second-GenerationAntimalarialsAntineoplastic Agents, AlkylatingBone Density Conservation AgentsCardiotonic AgentsCyclooxygenase InhibitorsDopamine Uptake InhibitorsFree Radical ScavengersHistamine H1 Antagonists, Non-SedatingHistamine H2 AntagonistsHypoglycemic AgentsNitric Oxide DonorsPurinergic P1 Receptor AntagonistsRodenticidesSodium Potassium Chloride Symporter InhibitorsTopoisomerase II Inhibitors===== phenotype 23=================================================================proportion of pts: 0.0987124463519lambda: 234.263809976----------------------------------------Malignant neoplasm of lymphatic and hematopoietic tissueRheumatism, excluding the backNaRange name naAdrenergic beta-1 Receptor AntagonistsAdrenergic beta-2 Receptor AgonistsAnalgesics, Non-NarcoticAngiotensin II Type 1 Receptor BlockersAnti-Inflammatory AgentsAntidepressive Agents, Second-GenerationAntihypertensive AgentsAntimanic AgentsAntineoplastic Agents, HormonalAntiviral AgentsCardiotonic AgentsCyclooxygenase InhibitorsGABA ModulatorsHistamine H1 Antagonists, Non-SedatingHistamine H2 AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsHypolipidemic AgentsMineralocorticoid Receptor AntagonistsNANarcoticsNucleic Acid Synthesis InhibitorsProton Pump InhibitorsRodenticidesSerotonin Receptor AgonistsSurface-Active AgentsSympathomimeticsTopoisomerase II InhibitorsTranquilizing AgentsVasodilator AgentsVitamin B ComplexVoltage-Gated Sodium Channel Blockers===== phenotype 25=================================================================proportion of pts: 0.108726752504lambda: 212.089280457----------------------------------------NaHypertensive diseaseRheumatism, excluding the backGeneral symptomsAdrenergic beta-1 Receptor AntagonistsAndrogensAnti-Allergic AgentsAnti-Bacterial AgentsAntimanic AgentsAntiviral AgentsBone Density Conservation AgentsCyclooxygenase 2 InhibitorsDopamine Uptake InhibitorsEpithelial Sodium Channel BlockersGABA ModulatorsHistamine H1 AntagonistsImmunosuppressive AgentsNANarcoticsNeuroprotective AgentsProgestinsSodium Chloride Symporter InhibitorsVitamin B Complex===== phenotype 49=================================================================proportion of pts: 0.0915593705293lambda: 204.265454407----------------------------------------Organic psychotic conditionsRheumatism, excluding the backOperations on the musculoskeletal systemGeneral symptomsAdrenergic alpha-1 Receptor AntagonistsAnalgesics, Non-NarcoticAnti-Allergic AgentsAnti-Bacterial AgentsAnti-Inflammatory AgentsAntidepressive Agents, Second-GenerationAntimanic AgentsAntimutagenic AgentsAntineoplastic AgentsAntineoplastic Agents, HormonalAntioxidantsAntipsychotic AgentsBone Density Conservation AgentsCardiotonic AgentsCyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDopamine Uptake InhibitorsEstrogensGABA ModulatorsGastrointestinal AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsNANarcoticsNitric Oxide DonorsNootropic AgentsProton Pump InhibitorsSodium Potassium Chloride Symporter InhibitorsSurface-Active AgentsSweetening AgentsVasodilator AgentsVitamin B Complex===== phenotype 14=================================================================proportion of pts: 0.118741058655lambda: 201.904278754----------------------------------------Hypertensive diseaseOther diseases of skin and subcutaneous tissueSymptoms involving respiratory system and other chest symptomsRange name naAndrogensAnti-Allergic AgentsAnti-Bacterial AgentsAnti-Obesity AgentsAntimutagenic AgentsAntineoplastic Agents, HormonalAntioxidantsDopamine AntagonistsGABA ModulatorsGastrointestinal AgentsHistamine H1 Antagonists, Non-SedatingHypoglycemic AgentsImmunosuppressive AgentsIndicators and ReagentsMuscle Relaxants, CentralSerotonin 5-HT1 Receptor AgonistsTrace ElementsVitamin B ComplexVitaminsVoltage-Gated Sodium Channel Blockers===== phenotype 36=================================================================
proportion of pts: 0.32904148784
lambda: 798.418021768
----------------------------------------
Disorders of the peripheral nervous system
Disorders of the eye and adnexa
Arthropathies and related disorders
Dorsopathies
Rheumatism, excluding the back
Symptoms involving skin and other integumentary tissue
Analgesics, Non-Narcotic
Anti-Allergic Agents
Anti-Bacterial Agents
Antihypertensive Agents
Antimanic Agents
Antineoplastic Agents, Hormonal
Bone Density Conservation Agents
Cyclooxygenase Inhibitors
Histamine H1 Antagonists, Non-Sedating
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
NA
Nitric Oxide Donors
Purinergic P2Y Receptor Antagonists
Sodium Potassium Chloride Symporter Inhibitors
Sweetening Agents
Vasodilator Agents
Vitamin B Complex
===== phenotype 45=================================================================
proportion of pts: 0.22460658083
lambda: 712.414755598
----------------------------------------
Disorders of the eye and adnexa
Diseases of veins and lymphatics, and other diseases of circulatory system
Diseases of esophagus, stomach, and duodenum
Other inflammatory conditions of skin and subcutaneous tissue
Other diseases of skin and subcutaneous tissue
Symptoms involving cardiovascular system
Symptoms involving urinary system
14-alpha Demethylase Inhibitors
Adrenergic alpha-1 Receptor Antagonists
Adrenergic beta-1 Receptor Antagonists
Analgesics, Non-Narcotic
Angiotensin II Type 1 Receptor Blockers
Anti-Allergic Agents
Anti-Anxiety Agents
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Antidepressive Agents, Second-Generation
Antihypertensive Agents
Antimanic Agents
Cardiotonic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Estrogens
Free Radical Scavengers
GABA-A Receptor Agonists
Glucocorticoids
Histamine H1 Antagonists, Non-Sedating
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
Immunosuppressive Agents
Mineralocorticoid Receptor Antagonists
NA
Narcotics
Proton Pump Inhibitors
Sodium Chloride Symporter Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Topoisomerase II Inhibitors
===== phenotype 34=================================================================
proportion of pts: 0.290414878398
lambda: 667.624130214
----------------------------------------
Diabetes
Disorders of lipoid metabolism
Hypertensive disease
Nonspecific findings on examination of blood
Range name na
Adrenergic beta-1 Receptor Antagonists
Analgesics, Non-Narcotic
Angiotensin II Type 1 Receptor Blockers
Anti-Inflammatory Agents
Antihypertensive Agents
Bone Density Conservation Agents
Cyclooxygenase Inhibitors
Glucocorticoids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
NA
Proton Pump Inhibitors
Rodenticides
Surface-Active Agents
Vitamin B Complex
Vitamins
===== phenotype 26=================================================================
proportion of pts: 0.247496423462
lambda: 653.322573129
----------------------------------------
Diseases of veins and lymphatics, and other diseases of circulatory system
Acute respiratory infections
Other diseases of the upper respiratory tract
Infections of skin and subcutaneous tissue
Other diseases of skin and subcutaneous tissue
Symptoms involving head and neck
14-alpha Demethylase Inhibitors
Adrenergic alpha-1 Receptor Antagonists
Adrenergic beta-1 Receptor Antagonists
Analgesics, Non-Narcotic
Angiotensin II Type 1 Receptor Blockers
Antacids
Anti-Allergic Agents
Anti-Bacterial Agents
Antidepressive Agents, Second-Generation
Antihypertensive Agents
Antimalarials
Antimanic Agents
Bone Density Conservation Agents
Cyclooxygenase Inhibitors
Histamine H1 Antagonists, Non-Sedating
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mineralocorticoid Receptor Antagonists
Muscarinic Antagonists
NA
Rodenticides
Sodium Chloride Symporter Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Vasodilator Agents
Vitamins
===== phenotype 5=================================================================
proportion of pts: 0.218884120172
lambda: 628.178684221
----------------------------------------
Anemias
Organic sleep disorders
Diseases of oral cavity, salivary glands, and jaws
Arthropathies and related disorders
Symptoms involving head and neck
Sprains and strains of joints and adjacent muscles
Adrenergic beta-1 Receptor Antagonists
Analgesics, Non-Narcotic
Angiotensin II Type 1 Receptor Blockers
Anti-Allergic Agents
Anti-Bacterial Agents
Anti-Inflammatory Agents
Antidepressive Agents, Second-Generation
Antihypertensive Agents
Antimanic Agents
Antiviral Agents
Bone Density Conservation Agents
Cardiotonic Agents
Cyclooxygenase Inhibitors
Dopamine Uptake Inhibitors
GABA Modulators
GABA-A Receptor Agonists
Gastrointestinal Agents
Histamine H1 Antagonists
Histamine H1 Antagonists, Non-Sedating
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
Mineralocorticoid Receptor Antagonists
NA
Narcotics
Nitric Oxide Donors
Proton Pump Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Sweetening Agents
Vasodilator Agents
Vitamin B Complex
===== phenotype 15=================================================================
proportion of pts: 0.203147353362
lambda: 602.848928243
----------------------------------------
Disorders of thyroid gland
Disorders of lipoid metabolism
Disorders of the eye and adnexa
Hypertensive disease
General symptoms
Symptoms involving respiratory system and other chest symptoms
Range name na
14-alpha Demethylase Inhibitors
Adrenergic alpha-2 Receptor Agonists
Antacids
Anti-Bacterial Agents
Antihypertensive Agents
Antimutagenic Agents
Bone Density Conservation Agents
Cardiotonic Agents
Cyclooxygenase 2 Inhibitors
Epithelial Sodium Channel Blockers
GABA Modulators
Histamine H1 Antagonists
Hydroxymethylglutaryl-CoA Reductase Inhibitors
NA
Neuroprotective Agents
Nicotinic Agonists
Sodium Chloride Symporter Inhibitors
Vitamin B Complex
Vitamins
===== phenotype 20=================================================================
proportion of pts: 0.247496423462
lambda: 594.170835442
----------------------------------------
Disorders of lipoid metabolism
Diseases of the ear and mastoid process
Hypertensive disease
Other diseases of the upper respiratory tract
Other diseases of skin and subcutaneous tissue
Symptoms involving respiratory system and other chest symptoms
Adrenergic beta-1 Receptor Antagonists
Anti-Allergic Agents
Anti-Bacterial Agents
Antidepressive Agents, Second-Generation
Antihypertensive Agents
Antimanic Agents
Antiviral Agents
Bone Density Conservation Agents
Cardiotonic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Estrogens
GABA Modulators
Histamine H1 Antagonists, Non-Sedating
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
Immunosuppressive Agents
Muscle Relaxants, Central
NA
Narcotics
Parasympatholytics
Proton Pump Inhibitors
Topoisomerase II Inhibitors
Vasodilator Agents
===== phenotype 13=================================================================
proportion of pts: 0.195994277539
lambda: 561.36963012
----------------------------------------
Neurotic, personality, nonpsychotic disorders
Diseases of arteries, arterioles, and capillaries
Arthropathies and related disorders
Rheumatism, excluding the back
Abnormal results of function studies
Range name na
Adrenergic alpha-1 Receptor Antagonists
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-2 Receptor Agonists
Analgesics, Non-Narcotic
Anti-Asthmatic Agents
Anticholesteremic Agents
Antidepressive Agents, Second-Generation
Antihypertensive Agents
Cardiotonic Agents
Cyclooxygenase Inhibitors
Estrogens
Explosive Agents
GABA Modulators
GABA-A Receptor Agonists
Histamine H1 Antagonists
Histamine H2 Antagonists
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Muscle Relaxants, Central
NA
Parasympatholytics
Proton Pump Inhibitors
Sodium Chloride Symporter Inhibitors
Surface-Active Agents
Vasodilator Agents
===== phenotype 38=================================================================
proportion of pts: 0.241773962804
lambda: 554.53885211
----------------------------------------
Other diseases of urinary system
Other inflammatory conditions of skin and subcutaneous tissue
Dorsopathies
Symptoms involving cardiovascular system
Symptoms involving urinary system
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic beta-2 Receptor Agonists
Anesthetics, Intravenous
Anti-Bacterial Agents
Antihypertensive Agents
Antimanic Agents
Cardiotonic Agents
Cyclooxygenase Inhibitors
Dopamine Uptake Inhibitors
GABA Modulators
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Muscle Relaxants, Central
NA
Narcotics
Parasympatholytics
Surface-Active Agents
Sympathomimetics
Topoisomerase II Inhibitors
Vasodilator Agents
Vitamins
===== phenotype 37=================================================================
proportion of pts: 0.234620886981
lambda: 548.437988976
----------------------------------------
Hypertensive disease
Ischemic heart disease
Other diseases of urinary system
General symptoms
Symptoms involving urinary system
Range name na
Adrenergic alpha-1 Receptor Antagonists
Analgesics, Non-Narcotic
Anti-Allergic Agents
Antiviral Agents
Bone Density Conservation Agents
Dopamine Antagonists
Estrogens
Histamine H1 Antagonists
Histamine H1 Antagonists, Non-Sedating
Hypoglycemic Agents
Immunosuppressive Agents
NA
Sodium Chloride Symporter Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Topoisomerase II Inhibitors
Vitamin B Complex
Vitamins
===== phenotype 4=================================================================
proportion of pts: 0.178826895565
lambda: 543.130797274
----------------------------------------
Disorders of lipoid metabolism
Anemias
Hypertensive disease
Arthropathies and related disorders
Rheumatism, excluding the back
Osteopathies, chondropathies, and acquired musculoskeletal deformities
Range name na
14-alpha Demethylase Inhibitors
Adrenergic alpha-1 Receptor Antagonists
Angiotensin II Type 1 Receptor Blockers
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Antihypertensive Agents
Antimanic Agents
Cholinergic Antagonists
Free Radical Scavengers
GABA-A Receptor Agonists
Glucocorticoids
Hypoglycemic Agents
Immunosuppressive Agents
NA
Narcotics
Nucleic Acid Synthesis Inhibitors
Sodium Chloride Symporter Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Topoisomerase II Inhibitors
Trace Elements
Voltage-Gated Sodium Channel Blockers
===== phenotype 10=================================================================
proportion of pts: 0.231759656652
lambda: 542.409573015
----------------------------------------
Na
Disorders of the eye and adnexa
Chronic obstructive pulmonary disease and allied conditions
Other diseases of intestines and peritoneum
Infections of skin and subcutaneous tissue
Abnormal results of function studies
Adrenergic alpha-1 Receptor Antagonists
Analgesics, Non-Narcotic
Anti-Allergic Agents
Anti-Anxiety Agents
Anti-Bacterial Agents
Anti-Inflammatory Agents
Antineoplastic Agents, Hormonal
Antiviral Agents
Cardiotonic Agents
Cholinergic Antagonists
Cyclooxygenase Inhibitors
Dopamine Uptake Inhibitors
GABA-A Receptor Agonists
Histamine H1 Antagonists, Non-Sedating
Hypoglycemic Agents
Immunosuppressive Agents
NA
Narcotics
Proton Pump Inhibitors
Sodium Chloride Symporter Inhibitors
Surface-Active Agents
Sympathomimetics
Vasodilator Agents
Vitamin B Complex
Voltage-Gated Sodium Channel Blockers
===== phenotype 33=================================================================
proportion of pts: 0.211731044349
lambda: 530.882656349
----------------------------------------
Nutritional deficiencies
Disorders of lipoid metabolism
Disorders of the eye and adnexa
Diseases of the ear and mastoid process
Hypertensive disease
Arthropathies and related disorders
Adrenergic alpha-1 Receptor Antagonists
Adrenergic beta-1 Receptor Antagonists
Analgesics, Non-Narcotic
Androgens
Angiotensin II Type 1 Receptor Blockers
Anti-Bacterial Agents
Anti-Inflammatory Agents, Non-Steroidal
Antimanic Agents
Cyclooxygenase Inhibitors
GABA Modulators
Gastrointestinal Agents
Hypoglycemic Agents
NA
Narcotics
Nootropic Agents
Phosphodiesterase 5 Inhibitors
Proton Pump Inhibitors
Sodium Chloride Symporter Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Surface-Active Agents
Vasodilator Agents
Vitamin B Complex
===== phenotype 46=================================================================
proportion of pts: 0.200286123033
lambda: 522.601866659
----------------------------------------
Diabetes
Disorders of lipoid metabolism
Hypertensive disease
Ischemic heart disease
Symptoms involving respiratory system and other chest symptoms
Range name na
Adrenergic alpha-1 Receptor Antagonists
Angiotensin II Type 1 Receptor Blockers
Anti-Bacterial Agents
Antimanic Agents
Antioxidants
Bone Density Conservation Agents
Chelating Agents
Cyclooxygenase Inhibitors
Explosive Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
Mineralocorticoid Receptor Antagonists
NA
Nitric Oxide Donors
Nootropic Agents
Sodium Potassium Chloride Symporter Inhibitors
Sweetening Agents
Vasodilator Agents
Vitamins
===== phenotype 1=================================================================
proportion of pts: 0.230329041488
lambda: 509.828991393
----------------------------------------
Disorders of lipoid metabolism
Hypertensive disease
Ischemic heart disease
Other forms of heart disease
Acute respiratory infections
Arthropathies and related disorders
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-2 Receptor Agonists
Anti-Allergic Agents
Anti-Asthmatic Agents
Antidepressive Agents, Second-Generation
Antihypertensive Agents
Cardiotonic Agents
Cholinergic Antagonists
Explosive Agents
GABA Modulators
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Proton Pump Inhibitors
Sodium Chloride Symporter Inhibitors
Sympatholytics
Tranquilizing Agents
Vitamins
===== phenotype 44=================================================================
proportion of pts: 0.233190271817
lambda: 505.643382186
----------------------------------------
Benign neoplasm of other parts of digestive system
Disorders of the eye and adnexa
Other diseases of intestines and peritoneum
Rheumatism, excluding the back
General symptoms
Symptoms involving respiratory system and other chest symptoms
Adrenergic alpha-1 Receptor Antagonists
Analgesics, Non-Narcotic
Angiotensin II Type 1 Receptor Blockers
Antihypertensive Agents
Cyclooxygenase Inhibitors
Explosive Agents
GABA Modulators
Glucocorticoids
Histamine H1 Antagonists, Non-Sedating
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
Hypolipidemic Agents
Immunosuppressive Agents
NA
Proton Pump Inhibitors
Sympathomimetics
Vasodilator Agents
Vitamins
===== phenotype 42=================================================================
proportion of pts: 0.217453505007
lambda: 496.957809084
----------------------------------------
Neurotic, personality, nonpsychotic disorders
Ischemic heart disease
Other disorders of female genital tract
General symptoms
Symptoms involving digestive system
Other symptoms involving abdomen and pelvis
Adrenergic Uptake Inhibitors
Adrenergic alpha-2 Receptor Agonists
Analgesics, Non-Narcotic
Anti-Allergic Agents
Anti-Bacterial Agents
Anti-Inflammatory Agents
Antihypertensive Agents
Antimanic Agents
Antiviral Agents
Cardiotonic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Estrogens
Expectorants
Explosive Agents
GABA Modulators
Glucocorticoids
Histamine H1 Antagonists, Non-Sedating
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
NA
Nucleic Acid Synthesis Inhibitors
Parasympatholytics
Serotonin Uptake Inhibitors
===== phenotype 43=================================================================
proportion of pts: 0.14878397711
lambda: 494.078025976
----------------------------------------
Overweight, obesity and other hyperalimentation
Other diseases of the blood
Drug dependence
Chronic obstructive pulmonary disease and allied conditions
Symptoms involving respiratory system and other chest symptoms
Ill-defined and unknown causes of morbidity and mortality
Miscellaneous diagnostic and therapeutic procedures
14-alpha Demethylase Inhibitors
Adrenergic Uptake Inhibitors
Adrenergic alpha-1 Receptor Antagonists
Adrenergic beta-1 Receptor Antagonists
Analgesics, Non-Narcotic
Angiotensin II Type 1 Receptor Blockers
Anti-Allergic Agents
Anti-Bacterial Agents
Antidepressive Agents, Second-Generation
Antihypertensive Agents
Antimanic Agents
Bone Density Conservation Agents
Cardiotonic Agents
Cyclooxygenase Inhibitors
Dopamine Uptake Inhibitors
Fluorescent Dyes
Glucocorticoids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
Mineralocorticoid Receptor Antagonists
NA
Nootropic Agents
Proton Pump Inhibitors
Sodium Chloride Symporter Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Topoisomerase II Inhibitors
Tubulin Modulators
Vasodilator Agents
===== phenotype 24=================================================================
proportion of pts: 0.211731044349
lambda: 493.535553651
----------------------------------------
Acute respiratory infections
Pneumonia and influenza
Congenital anomalies
Symptoms involving digestive system
Abnormal results of function studies
Fractures
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-2 Receptor Agonists
Analgesics, Non-Narcotic
Angiotensin II Type 1 Receptor Blockers
Antacids
Anti-Bacterial Agents
Antimanic Agents
Bone Density Conservation Agents
Cardiotonic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
GABA Modulators
Histamine H1 Antagonists, Non-Sedating
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
Immunosuppressive Agents
NA
Proton Pump Inhibitors
Sodium Chloride Symporter Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Topoisomerase II Inhibitors
Vasodilator Agents
Vitamin B Complex
Vitamins
===== phenotype 29=================================================================
proportion of pts: 0.178826895565
lambda: 474.39163438
----------------------------------------
Neoplasm of uncertain behavior of other sites & tissues
Hypertensive disease
Other forms of heart disease
Other diseases of skin and subcutaneous tissue
Arthropathies and related disorders
Symptoms involving skin and other integumentary tissue
Adrenergic alpha-2 Receptor Agonists
Adrenergic beta-1 Receptor Antagonists
Anti-Allergic Agents
Antimanic Agents
Antineoplastic Agents, Hormonal
Antiviral Agents
Bone Density Conservation Agents
Cardiotonic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Epithelial Sodium Channel Blockers
GABA-A Receptor Agonists
Hypoglycemic Agents
NA
Proton Pump Inhibitors
Sodium Chloride Symporter Inhibitors
Surface-Active Agents
Vasodilator Agents
Vitamin B Complex
Vitamins
===== phenotype 12=================================================================
proportion of pts: 0.165951359084
lambda: 467.960820106
----------------------------------------
Symptoms involving skin and other integumentary tissue
Symptoms involving cardiovascular system
Fractures
Certain traumatic complications and unspecified injuries
Complications of surgical and medical care, not elsewhere classified
Range name na
Adrenergic alpha-2 Receptor Agonists
Adrenergic beta-1 Receptor Antagonists
Analgesics, Non-Narcotic
Angiotensin II Type 1 Receptor Blockers
Anti-Allergic Agents
Anti-Bacterial Agents
Anti-Inflammatory Agents
Antidepressive Agents, Second-Generation
Antihypertensive Agents
Antimalarials
Cathartics
Chelating Agents
Cyclooxygenase Inhibitors
Dopamine Antagonists
Dopamine Uptake Inhibitors
Enzyme Inhibitors
Free Radical Scavengers
GABA Modulators
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Immunosuppressive Agents
NA
Nucleic Acid Synthesis Inhibitors
Proton Pump Inhibitors
Sodium Chloride Symporter Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Topoisomerase II Inhibitors
Trace Elements
Vasodilator Agents
Voltage-Gated Sodium Channel Blockers
===== phenotype 28=================================================================
proportion of pts: 0.153075822604
lambda: 456.559506186
----------------------------------------
Mycoses
Disorders of the peripheral nervous system
Other diseases of the upper respiratory tract
Other diseases of urinary system
Symptoms involving skin and other integumentary tissue
Nonspecific findings on examination of blood
14-alpha Demethylase Inhibitors
Adrenergic Uptake Inhibitors
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-2 Receptor Agonists
Analgesics, Non-Narcotic
Anti-Allergic Agents
Anti-Asthmatic Agents
Anti-Bacterial Agents
Antimanic Agents
Antineoplastic Agents, Hormonal
Antitussive Agents
Bone Density Conservation Agents
Cardiotonic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
GABA Modulators
Gastrointestinal Agents
Histamine H2 Antagonists
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
Mineralocorticoid Receptor Antagonists
Muscle Relaxants, Central
NA
Nucleic Acid Synthesis Inhibitors
Proton Pump Inhibitors
Serotonin 5-HT1 Receptor Agonists
Serotonin Uptake Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Sympathomimetics
Topoisomerase II Inhibitors
Vasodilator Agents
Voltage-Gated Sodium Channel Blockers
===== phenotype 31=================================================================
proportion of pts: 0.174535050072
lambda: 451.652998792
----------------------------------------
Anemias
Coagulation or hemorrhagic diseases
Drug dependence
Cerebrovascular disease
Symptoms involving nervous and musculoskeletal systems
Miscellaneous diagnostic and therapeutic procedures
Adrenergic alpha-1 Receptor Antagonists
Adrenergic beta-1 Receptor Antagonists
Analgesics, Non-Narcotic
Anti-Bacterial Agents
Antihypertensive Agents
Antimanic Agents
Antineoplastic Agents, Hormonal
Cardiotonic Agents
Cathartics
Cyclooxygenase Inhibitors
Free Radical Scavengers
Histamine H1 Antagonists
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
NA
Narcotics
Proton Pump Inhibitors
Purinergic P2Y Receptor Antagonists
Rodenticides
Sodium Chloride Symporter Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Surface-Active Agents
Sweetening Agents
Sympathomimetics
Vasodilator Agents
Vitamin B Complex
Vitamins
Voltage-Gated Sodium Channel Blockers
===== phenotype 35=================================================================
proportion of pts: 0.171673819742
lambda: 435.236534596
----------------------------------------
Nutritional deficiencies
Diseases of the ear and mastoid process
Other diseases of intestines and peritoneum
Osteopathies, chondropathies, and acquired musculoskeletal deformities
General symptoms
Adrenergic alpha-2 Receptor Agonists
Adrenergic beta-1 Receptor Antagonists
Analgesics, Non-Narcotic
Angiotensin II Type 1 Receptor Blockers
Anti-Allergic Agents
Anti-Asthmatic Agents
Anti-Bacterial Agents
Antidepressive Agents, Second-Generation
Antihypertensive Agents
Bone Density Conservation Agents
Cyclooxygenase Inhibitors
Explosive Agents
Glucocorticoids
Histamine H1 Antagonists, Non-Sedating
Mineralocorticoid Receptor Antagonists
NA
Narcotics
Proton Pump Inhibitors
Sodium Chloride Symporter Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Topoisomerase II Inhibitors
Vitamin B Complex
Vitamins
===== phenotype 7=================================================================
proportion of pts: 0.218884120172
lambda: 434.432836433
----------------------------------------
Other bacterial diseases
Malignant neoplasm of skin
Diseases of other endocrine glands
Anemias
Hereditary and degenerative diseases of the central nervous system
Diseases of male genital organs
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic beta-1 Receptor Antagonists
Analgesics, Non-Narcotic
Anti-Allergic Agents
Anti-Bacterial Agents
Antidepressive Agents, Second-Generation
Antihypertensive Agents
Antimanic Agents
Cardiotonic Agents
Cyclooxygenase Inhibitors
GABA Modulators
Histamine H1 Antagonists, Non-Sedating
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
Mineralocorticoid Receptor Antagonists
NA
Proton Pump Inhibitors
Rodenticides
Sodium Potassium Chloride Symporter Inhibitors
Vasodilator Agents
Vitamin B Complex
===== phenotype 19=================================================================
proportion of pts: 0.168812589413
lambda: 414.326604824
----------------------------------------
Overweight, obesity and other hyperalimentation
Pain
Other disorders of the central nervous system
Chronic obstructive pulmonary disease and allied conditions
Hernia of abdominal cavity
Symptoms involving skin and other integumentary tissue
Nonspecific abnormal findings on radiological and other examination of body structure
Adrenergic alpha-2 Receptor Agonists
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-2 Receptor Agonists
Analgesics, Non-Narcotic
Anti-Allergic Agents
Anti-Asthmatic Agents
Anti-Bacterial Agents
Antidepressive Agents, Second-Generation
Antimanic Agents
Antioxidants
Calcium Channel Blockers
Cardiotonic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Explosive Agents
GABA Modulators
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
Immunosuppressive Agents
NA
Narcotics
Nicotinic Agonists
Parasympatholytics
Proton Pump Inhibitors
Purinergic P2Y Receptor Antagonists
Serotonin 5-HT1 Receptor Agonists
Sodium Potassium Chloride Symporter Inhibitors
Surface-Active Agents
Vasodilator Agents
Vitamins
===== phenotype 2=================================================================
proportion of pts: 0.155937052933
lambda: 411.689126705
----------------------------------------
Other diseases of the blood
Ischemic heart disease
Other forms of heart disease
General symptoms
Miscellaneous diagnostic and therapeutic procedures
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic beta-1 Receptor Antagonists
Analgesics, Non-Narcotic
Anti-Asthmatic Agents
Antihypertensive Agents
Antimalarials
Antimanic Agents
Antineoplastic Agents, Hormonal
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Epithelial Sodium Channel Blockers
Explosive Agents
Free Radical Scavengers
GABA Modulators
Gastrointestinal Agents
Histamine H1 Antagonists, Non-Sedating
NA
Narcotics
Nitric Oxide Donors
Proton Pump Inhibitors
Rodenticides
Sodium Chloride Symporter Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Surface-Active Agents
Topoisomerase II Inhibitors
Vasodilator Agents
===== phenotype 3=================================================================
proportion of pts: 0.18025751073
lambda: 411.37035428
----------------------------------------
Nutritional deficiencies
Dorsopathies
Rheumatism, excluding the back
Symptoms involving respiratory system and other chest symptoms
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-2 Receptor Agonists
Analgesics, Non-Narcotic
Angiotensin II Type 1 Receptor Blockers
Anti-Allergic Agents
Anti-Asthmatic Agents
Bone Density Conservation Agents
Cardiotonic Agents
Cyclooxygenase Inhibitors
GABA-A Receptor Agonists
Histamine H2 Antagonists
Hydroxymethylglutaryl-CoA Reductase Inhibitors
NA
Proton Pump Inhibitors
Sympathomimetics
Vasodilator Agents
Vitamin B Complex
Vitamins
===== phenotype 16=================================================================
proportion of pts: 0.125894134478
lambda: 386.378377766
----------------------------------------
Hypertensive disease
Other forms of heart disease
Nephritis, nephrotic syndrome, and nephrosis
Arthropathies and related disorders
Symptoms involving respiratory system and other chest symptoms
Adrenergic Uptake Inhibitors
Adrenergic beta-1 Receptor Antagonists
Analgesics, Non-Narcotic
Angiotensin II Type 1 Receptor Blockers
Anti-Allergic Agents
Anti-Bacterial Agents
Antihypertensive Agents
Antimalarials
Antimanic Agents
Antineoplastic Agents, Alkylating
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Explosive Agents
GABA Modulators
Hypoglycemic Agents
Muscarinic Antagonists
NA
Proton Pump Inhibitors
Purinergic P2Y Receptor Antagonists
Rodenticides
Sodium Chloride Symporter Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Sympathomimetics
Vasodilator Agents
Voltage-Gated Sodium Channel Blockers
===== phenotype 0=================================================================
proportion of pts: 0.171673819742
lambda: 383.577317643
----------------------------------------
Hypertensive disease
Acute respiratory infections
Other diseases of intestines and peritoneum
Arthropathies and related disorders
General symptoms
Range name na
Adrenergic alpha-1 Receptor Antagonists
Analgesics, Non-Narcotic
Anesthetics, Intravenous
Angiotensin II Type 1 Receptor Blockers
Antacids
Anti-Anxiety Agents
Antimanic Agents
GABA Modulators
GABA-A Receptor Agonists
Hypoglycemic Agents
Mineralocorticoid Receptor Antagonists
NA
Neuroprotective Agents
Proton Pump Inhibitors
Serotonin Uptake Inhibitors
Sympathomimetics
Topoisomerase II Inhibitors
Vasodilator Agents
Vitamin B Complex
===== phenotype 18=================================================================
proportion of pts: 0.135908440629
lambda: 381.124360381
----------------------------------------
Hypertensive disease
Diseases of male genital organs
Other inflammatory conditions of skin and subcutaneous tissue
Dorsopathies
Symptoms involving respiratory system and other chest symptoms
Range name na
Adrenergic alpha-1 Receptor Antagonists
Adrenergic beta-1 Receptor Antagonists
Analgesics, Non-Narcotic
Antacids
Anti-Allergic Agents
Anti-Asthmatic Agents
Anti-Bacterial Agents
Antidepressive Agents, Second-Generation
Antihypertensive Agents
Antioxidants
Antiviral Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Dopamine Uptake Inhibitors
Enzyme Inhibitors
Free Radical Scavengers
GABA-A Receptor Agonists
Histamine H1 Antagonists, Non-Sedating
Histamine H2 Antagonists
Mineralocorticoid Receptor Antagonists
NA
Parasympatholytics
Proton Pump Inhibitors
Purinergic P1 Receptor Antagonists
Sodium Chloride Symporter Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Trace Elements
Vasodilator Agents
Viscosupplements
Vitamins
===== phenotype 40=================================================================
proportion of pts: 0.113018597997
lambda: 376.110559002
----------------------------------------
Other bacterial diseases
Neurotic, personality, nonpsychotic disorders
Other diseases of respiratory system
Other diseases of intestines and peritoneum
Operations on the musculoskeletal system
Other and unspecified effects of external causes
14-alpha Demethylase Inhibitors
Adrenergic Uptake Inhibitors
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Analgesics, Non-Narcotic
Angiotensin II Type 1 Receptor Blockers
Anti-Bacterial Agents
Anti-Infective Agents, Local
Anti-Inflammatory Agents
Antidepressive Agents, Second-Generation
Antihypertensive Agents
Bone Density Conservation Agents
Cardiotonic Agents
Cariostatic Agents
Cathartics
Chelating Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Free Radical Scavengers
GABA Modulators
Glucocorticoids
Hematinics
Histamine H2 Antagonists
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
NA
Nucleic Acid Synthesis Inhibitors
Proton Pump Inhibitors
Serotonin Uptake Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Surface-Active Agents
Sympathomimetics
Vasodilator Agents
Vitamins
===== phenotype 41=================================================================
proportion of pts: 0.171673819742
lambda: 366.756404651
----------------------------------------
Disorders of breast
Other disorders of female genital tract
Symptoms concerning nutrition, metabolism, and development
Certain traumatic complications and unspecified injuries
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic beta-1 Receptor Antagonists
Analgesics, Non-Narcotic
Angiotensin II Type 1 Receptor Blockers
Anti-Allergic Agents
Antidepressive Agents, Second-Generation
Antimanic Agents
Antimutagenic Agents
Bone Density Conservation Agents
Cardiotonic Agents
Cyclooxygenase Inhibitors
GABA Modulators
GABA-A Receptor Agonists
Histamine H1 Antagonists, Non-Sedating
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
Hypolipidemic Agents
Immunosuppressive Agents
NA
Narcotics
Proton Pump Inhibitors
Rodenticides
Sodium Chloride Symporter Inhibitors
Sodium Potassium Chloride Symporter Inhibitors
Surface-Active Agents